Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Zymeworks Inc. logoZymeworks Inc.

ZYME · Nasdaq · USD · Market cap $1.8B · 243 employees

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.

FAIL · Does not pass the screen
26.14 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price26.14 USD at the 20 Nov 2026 close
  • Our value readFair vs our fair value, as of 20 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.42)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $24.01 to $27.62, base estimate $24.01 (screen dated 2026-11-20).

Current read
Markup ?
Fair · screened 2026-11-20
  • Trend Markup
  • Insiders insiders sold, $357,557, latest filing 2026-10-09
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.42, read 2026-11-19
  • Ethical does not pass the values gate
Price26.14 USD
Fair value24.01
Ethical score70.0/100
Value readFairas of 20 Nov 2026
Our investment reviews on this name
2026-11-08Read Markup29.63-11.8% to today Accumulation gives way to Markup first Markup read since November
2026-11-05Read Accumulation30.94-15.5% to today Markup gives way to Accumulation after an 8% rise in 4 days
2026-11-01Read Markup28.61-8.6% to today Distribution gives way to Markup first Markup read since September
2026-10-25Read Distribution28.12-7.0% to today ✓Markdown gives way to Distribution after a 10% rise in 2 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Zymeworks Inc. holds its Markup at $26.14. The statistical read favours the sellers, held for 4 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateThe statistical read favours the sellers, held for 4 days
Price at the screen$26.14
Valuation48.75 trailing · 87.10 forward price to earnings
Values screenFAIL · score 70.0
Beta1.30
The Workings

Five Screens: ZYME's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 5.27% Below 33% Pass
Interest-bearing cash 54.15% Below 33% Fail
Receivables 13.22% Below 49% Pass
Revenue purity 12.60% Below 5% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Zymeworks's business is fine, but its cash and interest-bearing securities are about 54% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when ZYME's ethical verdict changes

Today ZYME does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Fair to fair value, as of 20 Nov 2026: it trades above our $24.01 fair value estimate, 828.70% revenue growth.

Method.

24.01Conservative24.01Base case27.62Growth case 26.14Price

USD, 2026-11-20 screen. The price runs 8.9% over base.

The Street's Range
35.00Street low 41.50Street average 60.00Street high 26.14Price

Street: 14 covering, consensus Strong Buy. Average target +59%.

Chart
The Business, in Plain Words

Biotech Pipeline Hits Revenue Freefall Wall

Picture a lab racing to craft the next cancer fighter while the cash register rings up losses instead of sales. Zymeworks builds antibody platforms for tough diseases yet just posted revenue growth of minus 91 percent and a profit margin of minus 126 percent. At 24 dollars against our fair value of 20 dollars the shares already price in miracles that the current numbers do not support.

We pass because the opportunity rating is none. Forward earnings sit at 85 times while return on equity runs at minus 42 percent and the moat stays unknown. Analyst targets cluster near 37 dollars but that optimism collides with an 18 percent negative margin of safety and a business still burning cash at scale.

The ethical screen clears yet the financial picture flags classic early stage biotech hazards: binary trial outcomes, dilution risk and the chance peak losses arrive before any durable product. Numbers this weak usually warn of further downside rather than hidden upside. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E87.1xcheap for a company growing this fast
Trailing P/E48.8xexpensive: the price assumes strong growth ahead
EPS, trailing0.53
EPS, forward0.30
Revenue growth+828.7%growing very fast
Profit margin16.3%healthy profit margins
Return on equity15.0%a solid return on shareholder capital
FCF yield-10.80%
Debt to equity0.21minimal debt: a conservative balance sheet
Current ratio3.30comfortably covers its short-term bills
Beta1.30moves a little more than the market
Short interest, float0.13%
52-week range21.52 - 31.97
Market cap$1.8B
Employees243

ZYME-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $26.04 -0.8% Entry 20
2026-11-16 Markup $26.24 -11.4% Entry 19
2026-11-09 Markup $29.63 +0.0% Entry 18
2026-11-08 Markup · changed $29.63 +0.0% Entry 17

The framework has shifted from accumulation to markup since the last review.

2026-11-07 Accumulation $29.63 +3.1% Entry 16
2026-11-06 Accumulation $28.74 -7.1% Entry 15
2026-11-05 Accumulation · changed $30.94 +2.7% Entry 14

The framework has shifted from markup to accumulation since the last review.

2026-11-04 Markup $30.13 +5.3% Entry 13
2026-11-03 Markup $28.61 +0.0% Entry 12
2026-11-02 Markup $28.61 +0.0% Entry 11

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on ZYME

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in ZYME's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · ZYME
DateInsiderTitleTypeSharesValue
2026-10-09 Schayowitz Adam EVP, Head of R, D S - Sale+OE 13,832 $357,557

Public filings, recorded as found. The full tape lives at Insider Intelligence.

The Political Ledger · Congressional Disclosures
Disclosures naming ZYME
DatePoliticianPartyTypeAmount
2026-09-29 Gil Cisneros Democrat sell 1K–15K
2026-09-29 Gil Cisneros Democrat sell 1K–15K
2026-09-29 Gil Cisneros Democrat sell 1K–15K
2026-09-29 Gil Cisneros Democrat sell 1K–15K
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $24.03 -4.9% · $951 -4.9%
2 months $26.32 -13.2% · $868 -13.2%
3 months $23.23 -1.6% · $984 -1.6%
6 months $24.94 -8.4% · $916 -8.4%
1 year $13.07 +74.8% · $1,748 +74.8%
2 years $8.97 +154.7% · $2,547 +154.7%
3 years $8.52 +168.2% · $2,682 +168.2%
5 years $37.73 -39.4% · $606 -39.4%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ZYME does next, these words stay.

Zymeworks Inc. · ZYME · Markup · $26.14
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.